Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3321-3324

  Buchler, Tomas ^a   Pavlik, Tomas ^b   Bortlicek, Zbynek ^b   Poprach, Alexandr ^c   Vyzula, Rostislav ^c   Abrahamova, Jitka ^a   Melichar, Bohuslav ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Renal cell carcinoma; Response; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE COURSE; DISEASE FREE SURVIVAL; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84880292228     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0293-x     Document Type: Article

References (7)

1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-56.
2. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-9.
3. Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol. 2012;23:395-401.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
6. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UN, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan M, Rha SY, Donskov F, North SA, Choueiri TK, Heng DYC. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). J Clin Oncol. 2011; 29 (suppl; abstr 4555).
7. Escudier B, Loomis AK, Kaprin A, Motzer R, Tomczak P, Tarazi J, Kim S, Gao F, Williams JA, Rini B. Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial). Eur J Cancer. 2011;47(Suppl 1):S505.